Human BCMA & NF-κB Reporter Recombinant Cell Line, HEK293 (CAT#: IOC-LX136)

Creative Biolabs has developed several immune checkpoint stable cell Lines expressing the most popular immune checkpoints to accelerate clients' immunotherapy discovery and clinical translation. The BCMA / NF-κB - HEK293 recombinant cell line has been transfected with full-length human BCMA cDNA (Genbank #NM_001192) under control of a CMV promoter for high constitutive expression. The NF-κB-luciferase reporter is also stably integrated into the genome. The firefly luciferase gene is controlled by four copies of the NF-κB Response Element upstream of a minimal promoter. Upon ligand binding, active BCMA will initiate the NF-κB signaling pathway, leading to expression of the NF-κB-controlled luciferase reporter. Which can be used in binding assays and functional assay.

Stable cell lines for increased reliability and reproducibility;
Protein expression at the cell surface validated by FACS or WB;

Human

HEK293

BCMA & NF-κB Reporter

B-Cell Maturation Antigen (BCMA), also known as CD269, is a cell surface receptor of the TNF receptor superfamily that recognizes B-Cell Activating Factor (BAFF). BCMA is preferentially expressed on mature B-lymphocytes and Multiple Myeloma (MM) cells. BCMA is a highly attractive target antigen for immunotherapy not only because of its restricted expression in non-malignant tissue, but also due to its almost universal expression on MM cells.